As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Alx Oncology Holdings Inc. The largest reported stake is venBio Global Strategic Fund, L.P.'s, at 9.99%. 15 filings are on record since August 14, 2025 (Schedule 13D/A, October 16, 2026).
Sell to companies like Alx Oncology Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: venBio Global Strategic Fund, L.P. · Sole voting: 0 · Shared voting: 4,307,034 · Sole dispositive: 0 · Shared dispositive: 4,307,034 · SCHEDULE 13D/A, 2026-10-16
- · Reporting person: TCG Crossover GP II, LLC · Sole voting: 0 · Shared voting: 2,827,739 · Sole dispositive: 0 · Shared dispositive: 2,827,739 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 7,231,560 · Shared voting: 0 · Sole dispositive: 7,327,850 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
- · Holder: LSV Associates, LLC · Percent: 2.2% · Shares: 1,549,132 · SCHEDULE 13D/A
- · Holder: HBM Healthcare Investments (Cayman) Ltd. · Percent: 6.5% · SCHEDULE 13G/A
Alx Oncology Holdings Inc has 15 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| venBio Global Strategic Fund, L.P. | 9.99% | 4,307,034 | SCHEDULE 13D/A, 2026-10-16 | 2026-10-14 |
| RA Capital Management, L.P. | 9.9% | 13,117,106 | SCHEDULE 13G, 2026-02-09 | 2026-02-02 |
| Redmile Group, LLC | 6.8% | 9,214,188 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| HBM Healthcare Investments (Cayman) Ltd. | 6.5% | 8,590,692 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 5.4% | 7,327,850 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| 4.2% | 5,655,487 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 | |
| LSV Associates, LLC | 2.2% | 1,549,132 | SCHEDULE 13D/A, 2026-05-27 | 2026-05-27 |
| Millennium Management LLC | 1.5% | 1,988,559 | SCHEDULE 13G/A, 2026-04-28 | 2026-03-31 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Alx Oncology Holdings Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Alx Oncology Holdings Inc and the records around it.
Alx Oncology Holdings Inc elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), IO Biotech, Inc. (Apr 2026), Upstream Bio, Inc. (Nov 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026), LB Pharmaceuticals Inc. (Aug 2026)
Watch Alx Oncology Holdings Inc
Get an email when Alx Oncology Holdings Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alx Oncology Holdings Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Alx Oncology Holdings Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alx Oncology Holdings Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| venBio Global Strategic Fund, L.P. | 0 | 4,307,034 | 0 | 4,307,034 | SCHEDULE 13D/A, 2026-10-16 |
| venBio Global Strategic Fund II L.P. | 0 | 8,453,038 | 0 | 8,453,038 | SCHEDULE 13D/A, 2026-10-16 |
| venBio Global Strategic GP, L.P. | 0 | 4,307,034 | 0 | 4,307,034 | SCHEDULE 13D/A, 2026-10-16 |
| venBio Global Strategic GP II, L.P. | 0 | 8,453,038 | 0 | 8,453,038 | SCHEDULE 13D/A, 2026-10-16 |
| venBio Global Strategic GP, Ltd. | 0 | 4,307,034 | 0 | 4,307,034 | SCHEDULE 13D/A, 2026-10-16 |
| venBio Global Strategic GP II, Ltd. | 0 | 8,453,038 | 0 | 8,453,038 | SCHEDULE 13D/A, 2026-10-16 |
| Goodman Corey S | 0 | 12,927,442 | 0 | 12,927,442 | SCHEDULE 13D/A, 2026-10-16 |
| BlackRock, Inc. | 7,231,560 | 0 | 7,327,850 | 0 | SCHEDULE 13G, 2026-07-27 |
| TCG Crossover GP II, LLC | 0 | 2,827,739 | 0 | 2,827,739 | SCHEDULE 13G/A, 2026-08-14 |
| TCG Crossover Fund II, L.P. | 0 | 2,827,739 | 0 | 2,827,739 | SCHEDULE 13G/A, 2026-08-14 |
| TCG Crossover GP III, LLC | 0 | 2,827,748 | 0 | 2,827,748 | SCHEDULE 13G/A, 2026-08-14 |
| TCG Crossover Fund III, L.P. | 0 | 2,827,748 | 0 | 2,827,748 | SCHEDULE 13G/A, 2026-08-14 |
| Chen Yu | 0 | 5,655,487 | 0 | 5,655,487 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Alx Oncology Holdings Inc by CUSIP 00166B105 and gives its principal executive office as 323 Allerton Avenue, South San Francisco, CA 94080 (SCHEDULE 13D/A, 2026-10-16).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On October 14, 2026, Fund I entered into an exchange agreement (the "Exchange Agreement") with the Issuer, pursuant to which Fund I agreed to surrender 253,826 shares of Common Stock for no consideration, and the Issuer agreed to issue to Fund I a pre-funded warrant (the "Pre-Funded Warrant") to purchase up to 253,826 shares of Common Stock.venBio Global Strategic Fund, L.P., SCHEDULE 13D/A, 2026-10-16
Purpose of Transaction (Item 4)
venBio Global Strategic Fund, L.P.
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The responses to Items 3 and 6 of this Amendment No. 2 are incorporated by reference herein. Mr. Goodman resigned from the Issuer's board of directors effective June 29, 2026.Item 4 of the SCHEDULE 13D/A filed 2026-10-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Redmile Group, LLC | 8.5% | SCHEDULE 13G/A |
| 2025-10-08 | Millennium Management LLC | 5.1% | SCHEDULE 13G |
| 2025-10-22 | Millennium Management LLC | 6% | SCHEDULE 13G/A |
| 2025-11-14 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-02-04 | venBio Global Strategic Fund, L.P. | 10% | SCHEDULE 13D/A |
| 2026-02-06 | Chen Yu | 9.9% | SCHEDULE 13G |
| 2026-02-09 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2026-04-28 | Millennium Management LLC | 1.5% | SCHEDULE 13G/A |
| 2026-05-15 | HBM Healthcare Investments (Cayman) Ltd. | 6.5% | SCHEDULE 13G/A |
| 2026-05-15 | Redmile Group, LLC | 6.8% | SCHEDULE 13G/A |
| 2026-05-27 | LSV Associates, LLC | 2.2% | SCHEDULE 13D/A |
| 2026-07-27 | BlackRock, Inc. | 5.4% | SCHEDULE 13G |
| 2026-08-14 | Chen Yu | 4.2% | SCHEDULE 13G/A |
| 2026-10-16 | venBio Global Strategic Fund, L.P. | 9.99% | SCHEDULE 13D/A |
Questions about who owns Alx Oncology Holdings Inc
Who owns Alx Oncology Holdings Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Alx Oncology Holdings Inc: venBio Global Strategic Fund, L.P. (9.99%, Schedule 13D/A, filed 2026-10-16), RA Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-02-09), Redmile Group, LLC (6.8%, Schedule 13G/A, filed 2026-05-15), HBM Healthcare Investments (Cayman) Ltd. (6.5%, Schedule 13G/A, filed 2026-05-15) and BlackRock, Inc. (5.4%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Alx Oncology Holdings Inc?
By the share each holder's latest filing reports, the largest holders of Alx Oncology Holdings Inc on this page are venBio Global Strategic Fund, L.P. (9.99%), RA Capital Management, L.P. (9.9%) and Redmile Group, LLC (6.8%).
When did venBio Global Strategic Fund, L.P. buy into Alx Oncology Holdings Inc?
The filings give report dates, not purchase dates. The earliest filing from venBio Global Strategic Fund, L.P. on this page is the Schedule 13D/A, filed 2026-02-04, reporting 10%; its latest, Schedule 13D/A filed 2026-10-16, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Alx Oncology Holdings Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 30, 2026 | Leadership change: Corey Goodman departs | — | Leadership changes | Source |
| April 13, 2026 | Leadership change: Jeff Knight appointed, Chief Development and Operating Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Alx Oncology Holdings Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.